Aron Markovics is an analytical and hardworking student who has profound interest in finance, world markets, and quantitative decisions. Aron is known to be accurate, curious and diligent. Being a great team worker, he always comes up with valuable observations and viewpoints during discussion sessions. Aron works best in a structured environment with high expectations, and he always applies diligence and professionalism to each task he performs.

MediWound develops enzymatic therapies for burns and chronic wounds, anchored by NexoBrid — an FDA-approved, surgery-sparing debridement treatment gaining traction in U.S. burn centers. The company sits at the intersection of rising demand for advanced wound care and hospital pressure to reduce OR time and staffing needs. With a lean cost structure and a clear path to scaling revenue, MediWound trades at a steep discount to wound-care peers despite differentiated tech and growing regulatory support. The upside case is straightforward: commercial ramp + pipeline validation driving a rerating as MDWD becomes a focused bet on next-gen debridement.